Eli Lilly and CoXSWX:LLY 100 PEG Ratio is 1.33 as of Jun. 27, 2026, which is 34% below its 10-year median of 2.03. GuruFocus rates XSWX:LLY with a GF Score™ of 100/100 and a GF Value™ of CHF1,111.74 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 347 Drug Manufacturers companies, Eli Lilly and Co ranks better than 59.94% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Eli Lilly and Co's PEG Ratio or its related term are showing as below:
XSWX:LLY'
s PEG Ratio Range Over the Past 10 Years
Min: 0.82 Med: 2.03 Max: 92.35
Current: 1.26
During the past 13 years, Eli Lilly and Co's highest PEG Ratio was 92.35. The lowest was 0.82. And the median was 2.03.
XSWX:LLY's PEG Ratio is ranked better than 59.94% of 347
companies
in the Drug Manufacturers industry
Industry Median: 1.71
vs XSWX:LLY: 1.26
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Eli Lilly and Co (XSWX:LLY) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Eli Lilly and Co PEG Ratio Related Terms
Eli Lilly and Co PEG Ratio Historical Data
* Premium members only.
The historical data trend for Eli Lilly and Co's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Eli Lilly and Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eli Lilly and Co PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Eli Lilly and Co's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Eli Lilly and Co (XSWX:LLY) has a PEG Ratio of 1.33 as of Jun. 27, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Eli Lilly and Co and its competitors. This is 34% below median its historical median of 2.03. Over the past decade, Eli Lilly and Co's PEG Ratio has ranged from 0.82 to 92.35. According to the industry distribution chart, Eli Lilly and Co ranks #139 out of 347 companies in the Drug Manufacturers industry, placing it in the top 40.1%.
Is Eli Lilly and Co's PEG Ratio too high?
Eli Lilly and Co's current PEG Ratio of 1.33 is 34% below median its 10-year median of 2.03. Over the past 10 years, this metric has ranged from a low of 0.82 to a high of 92.35. The Drug Manufacturers industry median PEG Ratio is 1.71. Eli Lilly and Co's value of 1.33 is 22.2% below this industry median. Based on the distribution chart, Eli Lilly and Co ranks #139 out of 347 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Eli Lilly and Co has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's PEG Ratio compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #139 out of 347 companies for PEG Ratio. This puts Eli Lilly and Co in the upper half of its industry. The industry median PEG Ratio is 1.71. Eli Lilly and Co's value of 1.33 is 22.2% below this benchmark. Historically, Eli Lilly and Co's own PEG Ratio has ranged from 0.82 to 92.35 over the past decade. While the company's 10-year median is 2.03 vs. the industry median of 1.71, Eli Lilly and Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.71, based on 347 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eli Lilly and Co's current PEG Ratio of 1.33 is 22.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Eli Lilly and Co and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eli Lilly and Co's current PEG Ratio is 1.33, which is 34% below median its own 10-year median of 2.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,111.74, compared to a current price of CHF955.00 — trading 14.1% below its estimated fair value. The current PEG Ratio is 1.33, which is 34% below median its 10-year median of 2.03 and 22.2% below the Drug Manufacturers industry median of 1.71. Eli Lilly and Co's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current PEG Ratio is 1.33 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?
Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued.
The current stock price of CHF955.00 is trading 14.1% below its estimated GF Value™ of CHF1,111.74.
GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.
Key valuation signals for XSWX:LLY:
PEG Ratio: 1.33 (34% below median its 10-year median of 2.03)
GF Value™: CHF1,111.74 vs. price of CHF955.00 (14.1% below fair value)
Industry Position: 22.2% below the Drug Manufacturers median (#139 of 347)
No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
100GF Score
Get the complete analysis for XSWX:LLY
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:LLY has been successfully added to your 
